Harrow (HROW) Convertible Debt (2010 - 2016)
Harrow (HROW) posted Convertible Debt of $914000.0 for Q3 2016, up 20.58% on a QoQ basis from $758000.0 in Q2 2016.
Powered by 
Analysis
Harrow (HROW) Convertible Debt (2010 - 2016) Analysis & Trends
Harrow has reported Convertible Debt for 3 years, with the latest figure at $914000.0 in Q3 2016.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $914000.0 in Q3 2016; TTM through Sep 2016 was $914000.0, a N/A change from a year earlier, with the FY2016 full-year figure at $914000.0, changed N/A from the prior year.
- Convertible Debt was $914000.0 for Q3 2016 at Harrow, up from $758000.0 in the prior quarter.
- The five-year high for Convertible Debt was $914000.0 in Q3 2016, with the low at $758000.0 in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2016 | 914,000.00 |
| Jun 30, 2016 | 758,000.00 |
| Dec 31, 2011 | 1.30 Mn |
| Dec 31, 2010 | 1.06 Mn |